Kornimate/medical-research-clean huggingface dataset:
the effectiveness of augmented reality to enhance cpap therapy in osa patients

Conditions: Aherence; Physical Symptoms; Mental Health; Quality of Life

Summary: the goal of this clinical trial is to exam if artificial reality works to improve continuous positive airway pressure (cpap) adherence in obstructive sleep apnea (osa) patients. it will also learn about the feasibility of ar guided cpap therapy. the main questions it aims to answer are: does ar guided cpap therapy increase the adherence of cpap therapy among osa patients? what barriers do participants have when using ar guided cpap therapy? researchers will compare ar guided cpap therapy to a control (standard of care) to see if ar guided cpap therapy works to enhance the adherence of cpap therapy. participants will: 1. take ar guided cpap therapy or standard of care every day for 6 months 2. visit the clinic on baseline (t0), receiving cpap therapy at the 1st month (t1), for checkups and tests, receiving cpap therapy at the 3rd month (t2), receiving cpap therapy at the 6th month (t3). 3. response their symptoms on each following time.

participants will randomly assign to two group, for experimental group will be received ar guided cpap therapy. in the control group will be received standard of care.

Eligibility criteria:
inclusion criteria: * (1) diagnosed with moderate to severe obstructive sleep apnea (ahi≥15) through polysomnography (psg). * (2) age is equal to or greater than 20 years old or equal. exclusion criteria: * (1) individuals who have previously used positive pressure ventilators for treatment, * (2) those diagnosed with central sleep apnea, * (3) those with uncontrolled acute mental illness, * (4) terminally ill patients.

Keywords: augmented reality (ar) continuous positive airway pressure (cpap) adherence symptoms change
ultrasound-based artificial intelligence for classification of carpal tunnel syndrome

Conditions: Carpal Tunnel Syndrome (CTS); Ultrasound; Artificial Intelligence (AI)

Summary: carpal tunnel syndrome (cts) is one of the most prevalent peripheral neuropathies, impacting approximately 4% of the general population. it is typically classified into three degrees: mild, moderate, and severe. accurate grading of carpal tunnel syndrome (cts) is essential for determining appropriate treatment options, thereby playing a crucial role in optimizing patient outcomes. electrophysiological testing (est) is a key parameter for grading carpal tunnel syndrome (cts). however, it is limited by several factors, including its invasive nature, poor reproducibility, and reduced sensitivity for detecting early-stage disease. recently, ultrasound has gained widespread acceptance among clinicians for the assessment and grading of cts. nonetheless, radiologists often encounter challenges in this process due to the variability in image quality, differences in experience, and inherent subjectivity. to address these issues, artificial intelligence presents a promising solution. therefore, this study aims to develop a deep learning model for grading cts by leveraging multimodal imaging features, including b-mode ultrasound, superb microvascular imaging (smi), and elastography. additionally, the investigators intend to validate the model's effectiveness by testing it with images from various clinical centers, ensuring its generalizability across different clinical settings.


Eligibility criteria:
inclusion criteria: * those who have complained about associated symptoms about cts, including pain, numbness, and weakness of hand. * those who perform ultrasound examinations of median nerve within 1 week of the symptom. * those who have electrophysilogical test results as reference standard. exclusion criteria: * those who had a surgery in the affected hand. * those who had a trauma or fracture in the affected hand. * those who had rheumatoid-related conditions, autoimmune diseases, and endocrine disorders.

Keywords: carpal tunnel syndrome ultrasound artificial intelligence
polymorphism of itga4 gene in chronic lymphocytic leukemia

Conditions: Chronic Lymphocytic Leukemia

Summary: chronic lymphocytic leukemia (cll) is a clonal lymphoproliferative disorder that is characterized by heterogeneous presentation at the clinical and molecular levels. itga4 protein has been found to be deregulated in cll with adverse clinical outcome. itga4 gene (cd49d) encodes a member of the integrin alpha chain family of proteins and is considered a negative prognosticator in cll with aggressive course and short time to treatment. the aim of the study: is to investigate itga4 gene expression pattern in cll.


Eligibility criteria:
inclusion criteria: * patients with newly diagnosed cll. exclusion criteria: * ▪ patients previously diagnosed as cll and received treatment before. * patients with other solid tumors.
living donor liver transplantation to patients with portal vein thrombosis

Conditions: Portal Vein Thrombosis; Liver Transplant; Complications

Summary: data of demographic, clinical, laboratory and imaging studies of living donor liver transplantation (ldlt) recipients from two transplant centers were collected. survival and morbidity rates between patients with and without portal vein thrombosis (pvt) were compared. risk factors of mortality in the setting of pvt were identified. intraoperative portal flow measurements were compared before and after portal flow restoration.

ldlts performed in two experienced centers (ankara university ibn-i sina hospital and ankara güven hospital) between january 2013 and february 2020 were evaluated and included in the cohort study. deceased donor liver transplants and pediatric transplants (deceased or living) were excluded from the study. data relating to this study including patient history, preoperative laboratory and imaging test results, reports of surgical procedures or interventions, intraoperative anesthesia records, post-operative laboratory trends, and postoperative complications were extracted from the computer-based data management system and prospectively maintained in transplant databases in both centers. recipients of ldlt were divided in two groups according to the presence or absence of pvt. portal flow measurements were recorded with veriq (medistim asa, oslo, norway) doppler flowmeter device in one of the centers later in the study period. the follow-up and recordings of the patients were maintained in the outpatient clinics of the two centers. the most serious complication experienced by each patient was recorded according to the clavien-dindo classification primary outcome of the current study was the survival rates of patients with and without pvt secondary outcomes of the study included morbidity in patients with and without pvt after ldlt, risk factors of mortality after ldlt to patients with pvt and comparison of intraoperative portal flow measurements between patients with and without pvt

Eligibility criteria:
inclusion criteria: * patients underwent liver transplantation exclusion criteria: * pediatric liver transplants * deceased donor liver transplants

Keywords: liver transplantation portal vein thrombosis thrombectomy doppler flowmeter
evaluation of optical genome mapping in phi negative myeloproliferative neoplasia in the detection of acquired cytogenetic abnormalities

Conditions: Myeloproliferative Neoplasm; Optical Genome Mapping; Cytogenetics; Clonality; Prognostic Stratification

Summary: standard cytogenetics (cba +/- fish) is of diagnostic and prognostic interest in ph- mpn. however, its value is limited by the low frequency of detected abnormalities. the development of tools to increase the sensitivity of detection of chromosomal alterations is therefore particularly adapted to these pathologies. optical genome mapping (ogm) is a high resolution "long read" technique that allows the identification of structural and copy number variations at the whole genome level. several recent studies suggest that ogm is a future tool for cytogenetic characterization of haematological disorders. its ability to describe structural abnormalities, including balanced ones, represents a major advantage over currently used technologies. thus, ogm seems to be the key tool for cytogenetics of haematological malignancies in the coming years, making it possible to replace, under certain conditions, not only karyotype and fish, but cma and even rt-mlpa for the search for fusion transcripts, thus filling in the gaps in these techniques while maintaining their advantages. to define the place of this technology in ph- mpn, the investigators will perform a ogm analysis on patients with ph-mpn for whom bone marrow exploration is scheduled. these results will be compared with those of standard cytogenetics (cba +/- fish).


Eligibility criteria:
inclusion criteria: * patient 18 years of age or older * diagnosis or follow-up of polycythemia vera, essential thrombocythemia or primary or secondary myelofibrosis * requires bone marrow cytogenetics at diagnosis or follow-up * understanding of the french language * information of the patient and collection of no objection * person affiliated to a social security regime exclusion criteria: * patient with bcr::abl positive myeloproliferative neoplasia. * person with a medical history that may impair the ability to understand the information notice

Keywords: myeloproliferative neoplasm optical genome mapping cytogenetics clonality prognostic stratification
human circadian sensitivity to very short light pulses

Conditions: Circadian Rhythm Disorders

Summary: the mammalian eye serves both visual and non-image-forming functions. new information about the non-image-forming anatomy and physiology of the eye has revealed effects of ocular light stimuli on human circadian rhythms, melatonin suppression, heart rate, pupillary reflexes, cognitive performance, alertness and sleep. the results of the proposed work can be used to make predictions about the effects of light, to make recommendations involving exposure to or avoidance of light, and to design environmental lighting, resulting in improved health and alertness and decreased errors and accidents.


Eligibility criteria:
inclusion criteria: * healthy volunteers exclusion criteria: * no medications * no eye disease * no sleep disorders * no psychiatric disorders

Keywords: circadian rhythms melatonin ocular light exposure darkness exposure performance alertness
magnetic resonance imaging in the diagnosis of pulmonary hypertension

Conditions: Pulmonary Hypertension; Ventricular Function; MR Phase Contrast Velocity Imaging; Late Enhancement Patterns

Summary: the aim of the present study is to identify changes in the cardiovascular system in patients with pulmonary hypertension (ph) by magnetic resonance imaging (mri). mri is accepted as golden standard method for the evaluation of left and right ventricular morphology and function. all patients who showed elevated pulmonary pressure in the right heart catheter investigation are assigned to mri. parameters derived from mri are included in the clinical and therapeutic decisions. well established as well as new mri parameters are evaluated and compared to the results of right heart catheter. further age-matched controls without known cardiac or pulmonary disease are investigated by native mri.

patients with suspected, latent and manifest ph and controls are investigated by mri according to the following protocol in breathhold or free breathing (depending on the patients' breath-hold abilities). in case of elevated creatinin values, no contrast agent is applied. * planning of cardiac views: planning of 2-chamber view, short axes view and 4-chamber view. * morphological overview: transversal and coronal haste images * left and right heart functional and valve evaluation: cine 2-chamber imaging, multi-slice cine 4-chamber imaging, cine left and right ventricular outflow tract imaging and multi-slice cine short axes imaging covering the left and right ventricle for evaluation of edv, esv, sv, ef, co and muscle mass. * phase contrast imaging: flow measurements in the aorta, the pulmonary artery and the heart. * perfusion measurement. * late enhancement measurement: multi-slice short axes view, multi-slice 2-chamber view and multi-slice 4-chamber view.

Eligibility criteria:
inclusion criteria: * controls without history of cardiac or pulmonary diseases * patients with suspected ph * patients with latent ph * patients with manifest ph exclusion criteria: * mri exclusion criteria
simulation in physical therapy students

Conditions: Simulation Training

Summary: this randomized trial included physiotherapy students, randomized in two groups, experimental one included simulation for developed competencies related to clinical reasoning in physiotherapy interventions for people with low back pain. the second group developed role-playing. this protocol allows us to compare two strategies with simulation for to promote clinical decisions in physiotherapy practice.

low back pain (lbp) is symptomatology with a high global prevalence; health professionals, including physiotherapists, must have the skills to create professional interaction plans that permit a better quality of life for consultants. clinical simulation can be a pedagogic setting that facilitates students with adequate training to acquire skills that improve professional reasoning in this clinical situation. the objective of this study was to compare the effects of clinical simulation with a simulated patient (sp) versus simulation with role-playing (rp) in physiotherapy students for decision-making in clinical skills while caring for a person with lbp. methods. an experimental study, with 42 participants from two colombian universities, randomized into two groups (sp n = 21, rp n = 21). the clinical skill was evaluated during the interaction with a person with lbp for which the objective structured clinical examination (osce-ml) was validated for individuals with low back pain; thereafter, a pedagogical method was conducted that included clinical simulation and, finally, the osce-ml was applied again to compare both groups.

Eligibility criteria:
inclusion criteria: * physiotherapy students in five-semester from universidad de la sabana and universidad de boyacá exclusion criteria: * under-age subjects * those who had been internally or externally transferred from another academic program in health, * exchange students * those repeating * with prior experiences in simulated practice in other assignments
nebulized dexmedetomidine for post-anesthesia delirium in preschool children

Conditions: Emergence Delirium; Delirium - Postoperative

Summary: analyzing the effectiveness of nebulized dexmedetomidine 2 mcg/kg in reducing the incidence of post-anesthesia delirium in preschool children undergoing elective surgery with sevoflurane inhalation general anesthesia. researchers will compare nebulized dexmedetomidine to a placebo (a look-alike substance that contains no drug) to see if the drug can reduce post anesthesia delirium incidence.

participant will : nebulized with the anesthetic drug dexmedetomidine at a dose of 2 mcg/kg body weight, diluted to 3 ml with 0.9% normal saline, is administered before the induction of anesthesia in the reception area. after the anesthesia, primary data collection is conducted by recovery room staff who are blinded to the treatment and control groups. data includes scores or levels of post-anesthesia delirium or agitation assessed using the pediatric anesthesia emergence delirium score (paed score) in the recovery room.

Eligibility criteria:
inclusion criteria: * pediatric patients aged 2 to 6 years old. * planned general anesthesia using inhalation sevoflurane with endotracheal tube techniques * parents agree to participate in the study exclusion criteria: * pediatric patients with \> asa ii. * difficult airway management. * emergency surgery. * congenital abnormalities of vital organs. * malnutrition * history or diagnosed with mental or cognitive disorders. * history of upper respiratory infection within 2 weeks before the procedure. * history of allergy to dexmedetomidine. * surgery duration estimation exceeding 180 minutes. * parents refuse to participate in the study

Keywords: nebulized dexmedetomidine post anesthesia delirium sevoflurane preschool
a study of oral upadacitinib tablets to assess the change in disease symptoms in adult canadian participants with moderate to severe rheumatoid arthritis

Conditions: Rheumatoid Arthritis (RA)

Summary: rheumatoid arthritis (ra) is an inflammatory disease of the joints causing pain, stiffness, swelling and loss of joint function. this study will assess how effective upadacitinib is in changing the disease symptoms in canadian participants with ra. upadacitinib is a drug approved for the treatment of moderately to severely active rheumatoid arthritis. adult canadian participants with moderate to severe ra who have been prescribed upadacitinib by their physicians will be enrolled. approximately, 390 participants will be enrolled this study, in multiple sites within canada. participants will receive upadacitinib as prescribed by the physician and will be followed for approximately 24 months. there will be no additional burden for participants in this trial compared to their standard of care. participants will attend regular visits during the course of the study at a hospital or clinic and will be asked to provide additional information by questionnaire at each visit.


Eligibility criteria:
inclusion criteria: * diagnosis of moderate to severe rheumatoid arthritis (ra) according to the investigator. * decision to initiate upa treatment by investigator according to the local product label independent of the participant's participation in the study. * has been previously treated with conventional synthetic disease-modifying antirheumatic drugs (csdmards) and corresponds to one of the following subgroups: * has not been previously exposed to any biologic disease-modifying antirheumatic drugs (bdmard) or targeted synthetic disease-modifying antirheumatic drugs (tsdmard). * has not been previously exposed to tsdmard and has been previously exposed to \<= 2 bdmards. * has been previously treated with one tsdmard and \<=1 bdmard prior to treatment with that tsdmard. exclusion criteria: * presence of any condition that, in the opinion of the treating physician, prohibits the participant from participating in the study or obscures the assessment of the treatment of ra. * diagnosis of rheumatic disease other than ra. * diagnosis of juvenile ra. * currently participating in an investigational clinical trial. * has prior exposure to a bdmard after exposure to a tsdmard. * has prior exposure to tsdmard in an investigational clinical trial.

Keywords: rheumatoid arthritis upadacitinib rinvoq
phase i trial of qh-1a hybrid bio-artificial liver with ex vivo blood-purifying mscs in acute-on-chronic liver failure

Conditions: Acute-On-Chronic Liver Failure

Summary: the goal of this phase i clinical trial is to evaluate the safety and efficacy of combining the qh-1a bioartificial liver device with mesenchymal stem cells（mscs） for blood purification in treating patients with acute-on-chronic liver failure, and to determine the optimal treatment duration and frequency for phase ii. the study will enroll patients aged 18 to 65 years who meet the diagnostic criteria for acute-on-chronic liver failure as outlined in the 2024 chinese liver failure clinical guidelines. the main questions this study aims to answer are: * does the combined therapy improve the 28-day survival rate after the final treatment? * does the qh-1a device in its hbal mode consistently achieve the predefined device performance pass rate? * do patients show significant improvements in their biochemical markers following treatment? * what is the immunogenicity profile of the mesenchymal stem cells used for blood purification? participants will be screened within 14 days before their first treatment and will be allocated into one of four groups based on treatment duration and frequency: * 4-hour group (3 patients) * 6-hour group (3 patients) * 8-hour group (3 patients) * multiple-treatment group (6 patients) treatment will be administered in a sequential escalation-from the 4-hour group up to the multiple-treatment group-based on safety data from a 28-day observation period, which will be reviewed by a safety evaluation committee. in addition, upon referral to the hepatitis b health clinic, participants will receive tailored health education, comprehensive liver function and virological assessments, and an individualized treatment and follow-up plan.


Eligibility criteria:
inclusion criteria: * age between 18 and 65 years, irrespective of gender. * patients with acute-on-chronic liver failure, diagnosed according to the - - guideline for diagnosis and treatment of liver failure (2024 version) in china. * subjects must provide informed consent prior to the study and voluntarily sign the written informed consent form. * subjects must be able to communicate effectively with the investigators and comply with the study protocol. exclusion criteria: * active bleeding or disseminated intravascular coagulation (dic) that is not effectively controlled. * allergies to the blood products or medications used during treatment. * circulatory failure. * occurrence of myocardial infarction, cerebral infarction, or cerebral hemorrhage within the past 6 months. * a history of malignant tumors within the past 5 years (except for cured basal cell carcinoma of the skin or carcinoma in situ of the cervix). * any other conditions that, in the opinion of the investigator, render the subject unsuitable for participation in the study.

Keywords: acute -on-chronic liver failure bio-artificial liver mesenchymal stem cells
topic compatibility lactoserum (dermacyd delicata - new fragrance)

Conditions: Hygiene

Summary: the purpose of this study is to demonstrate the absence of irritation potential (primary dermic irritability and cumulated dermic irritability) and allergy (sensibilization) of the product dermacyd femina delicata.


Eligibility criteria:
inclusion criteria: * phototypes: i, ii, iii and iv * integral skin test in the region exclusion criteria: * pregnancy or breastfeeding women * use of antinflammatory or immune-suppression drugs * personal history of atopy * history of sensibilization or irritation for topic products * active cutaneous disease * use of new drugs and/or cosmetics during the study the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.